Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Claudio Gobbi

Adjunct Professor

Università del Salento

Switzerland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Neurology

80%

Pharmacotherapy

30%

Multiple Sclerosis

70%

Neurodegenerative Disease

30%

Pharmacoepidemiology

20%

Infectious Disease

20%

Immunotherapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles16

Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies

Article Link

Year:

2024

Memory B cell–guided extended interval dosing of ocrelizumab in multiple sclerosis

Article Link

Year:

2024

Efficacy and safety of the implantable, magnetic resonance imaging‐compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients

Article Link

Year:

2024

Reply to: ‘Letter to the Editor: Neuropathies related to hepatitis E virus infection: First reported case in Europe’

Article Link

Year:

2024

Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®

Article Link

Year:

2024

Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study

Article Link

Year:

2023

Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis

Article Link

Year:

2023

Association of Brain Atrophy with Disease Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis

Article Link

Year:

2022

Nonlesional Sources of Contrast Enhancement on Postgadolinium “Black-Blood” 3D T1-SPACE Images in Patients with Multiple Sclerosis

Article Link

Year:

2022

Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry

Article Link

Year:

2022

Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping

Article Link

Year:

2022

Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies.

Article Link

Year:

2022

Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms

Article Link

Year:

2022

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: YES

Article Link

Year:

2022

Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis

Article Link

Year:

2022

Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).

Article Link

Year:

2022

Collaborators12

Paolo Maino

Head of Department

Università della Svizzera Italiana (USI)

SWITZERLAND

Daniela Distefano

SWITZERLAND

Özgür Yaldizli

SWITZERLAND

Maria Isabel Vargas

Prof. Dr

Hôpitaux Universitaires Genève

SWITZERLAND

Alessandro Ceschi

Professor

University of Applied Sciences of Southern Switzerland

SWITZERLAND

Giorgia Melli

Adjunct Professor

Università del Salento

SWITZERLAND

Philipp Eisele

GERMANY

Marco Kaufmann

University of Zurich

SWITZERLAND

Emanuele Pravatà

Assitant Professor

University “G. d’Annunzio” of Chieti-Pescara

ITALY

Mina Stanikić

University of Zurich

SWITZERLAND

Alessandro Cagol

SWITZERLAND

Gianna Carla Riccitelli

Co-Head Local Research Unit-INSI

SWITZERLAND

How do I reach out?

Meet Kite AI